These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 11249779)

  • 1. Technology evaluation: GEM-231, Hybridon Inc.
    Blay J
    Curr Opin Mol Ther; 2000 Aug; 2(4):468-72. PubMed ID: 11249779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GEM-231 (Hybridon).
    Blay J
    IDrugs; 2000 Sep; 3(9):1075-80. PubMed ID: 16049867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
    Cho YS; Cho-Chung YS
    Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technology evaluation: GEM-92, Hybridon Inc.
    Zheng R
    Curr Opin Mol Ther; 1999 Aug; 1(4):521-3. PubMed ID: 11713769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
    Cho YS; Kim MK; Tan L; Srivastava R; Agrawal S; Cho-Chung YS
    Clin Cancer Res; 2002 Feb; 8(2):607-14. PubMed ID: 11839683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology evaluation: MG-98, MethylGene.
    Zhang Z
    Curr Opin Mol Ther; 2001 Dec; 3(6):599-604. PubMed ID: 11804276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides targeting RI alpha subunit of protein kinase A. In vitro and in vivo anti-tumor activity and pharmacokinetics.
    Zhang R; Wang H
    Methods Mol Med; 2003; 75():637-54. PubMed ID: 12407769
    [No Abstract]   [Full Text] [Related]  

  • 9. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
    Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention with protein kinase A RIalpha antisense in DMBA-mammary carcinogenesis.
    Nesterova MV; Cho-Chung YS
    Ann N Y Acad Sci; 2005 Nov; 1058():255-64. PubMed ID: 16394142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancements of antisense oligonucleotides in treatment of breast cancer.
    Yang SP; Song ST; Song HF
    Acta Pharmacol Sin; 2003 Apr; 24(4):289-95. PubMed ID: 12676065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear translocation of the catalytic subunit of protein kinase A induced by an antisense oligonucleotide directed against the RIalpha regulatory subunit.
    Neary CL; Cho-Chung YS
    Oncogene; 2001 Nov; 20(55):8019-24. PubMed ID: 11753685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
    Morse MA
    Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotide technology in the development of cancer therapeutics.
    Tseng BY; Brown KD
    Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
    [No Abstract]   [Full Text] [Related]  

  • 15. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
    Kausch I; Böhle A
    Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis.
    Nesterova MV; Cho-Chung YS
    Clin Cancer Res; 2004 Jul; 10(13):4568-77. PubMed ID: 15240549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide.
    Fluiter K; Frieden M; Vreijling J; Rosenbohm C; De Wissel MB; Christensen SM; Koch T; Ørum H; Baas F
    Chembiochem; 2005 Jun; 6(6):1104-9. PubMed ID: 15861430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antisense nucleotides for therapy].
    Wang J; Wang L; Wang Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2006 Feb; 23(1):230-4. PubMed ID: 16532848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.
    Hu Y; Cherton-Horvat G; Dragowska V; Baird S; Korneluk RG; Durkin JP; Mayer LD; LaCasse EC
    Clin Cancer Res; 2003 Jul; 9(7):2826-36. PubMed ID: 12855663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotide therapy in urology.
    Kausch I; Böhle A
    J Urol; 2002 Jul; 168(1):239-47. PubMed ID: 12050550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.